NovaBridge Biosciences (NBP) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
PepGen (PEPG) has outperformed NovaBridge Biosciences (NBP) over the past year, losing 51.1% versus a loss of 68.6%. PepGen is the larger company by market cap ($166.0 million vs $158.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBP | PEPG |
|---|---|---|
| Share price | $1.37 | $2.40 |
| Market cap | $158.92M | $166.01M |
| 1-day change | -2.14% | +3.90% |
| YTD return | -65.58% | -63.13% |
| 1-year return | -68.65% | -51.12% |
| 5-year return | -97.92% | — |
| EPS (TTM) | $-0.67 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.79 | $7.80 |
| 52-week low | $1.31 | $1.31 |
| Distance from 52-week high | -79.82% | -69.23% |
| Analyst consensus | none | none |
| Avg. price target upside | +556.93% | +324.58% |
| Average volume | 387.52K | 976.87K |
| Shares outstanding | 116.00M | 69.17M |
| Employees | 30 | 57 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PEPG has outperformed NBP by 17.5 percentage points over the past year.
About NovaBridge Biosciences
NBP stock →NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Healthcare · Biotechnology · 30 employees
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Healthcare · Biotechnology · 57 employees
NBP vs PEPG FAQ
Which is bigger, NovaBridge Biosciences or PepGen?
PepGen (PEPG) is larger, with a market capitalization of $166.01M compared with $158.92M for NovaBridge Biosciences (NBP).
Which stock has performed better over the past year, NBP or PEPG?
PEPG returned -51.12% over the past 12 months, compared with -68.65% for NBP (price return, excluding dividends). Past performance does not predict future results.
Are NovaBridge Biosciences and PepGen in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.